《內地樓市》中指院:3月房企信用債發行總量按年及按月均穩步上升
中指研究院公布數據顯示,3月房企信用債發行總量按年及按月均穩步上升,發行進入穩定區間。中指研究院認為,伴隨「三支箭」等融資利好政策的持續釋放,可見當前融資環境確實正在回暖,特別是境內信用債,今年首季信用債月度發行額按年由負轉正,累計發行額按年增長11.6%。
不過,海外債、信託及ABS等渠道發行規模仍在下降通道,特別是信託等非標渠道,投放規模持續壓降,表明投資人對行業風險仍有顧慮和考量,多數投資人仍在持續觀察銷售市場復甦進度。由於當前銷售市場復甦的結構性,投資人對民企發債的各項要求仍然存在,拉高民企發債實際成本。隨著市場持續回暖,相信行業信心得以修復,融資效率將有進一步釋放的空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.